Gossamer Bio's Seralutinib Shows Long-Term Promise with Upcoming Catalysts

Gossamer Bio's seralutinib has shown promising results in treating pulmonary conditions, with sustained improvements in hemodynamics and functional gains over 72 weeks. A literature review reinforces confidence in the drug's durability and disease-modifying effect. Upcoming catalysts, including Phase 3 PROSERA trial results in February 2026, are expected to further validate seralutinib's efficacy and safety. H.C. Wainwright and Leerink Partners have reiterated their Buy ratings on Gossamer Bio with price targets of $10 and $6, respectively.

Title: Gossamer Bio's Seralutinib Shows Promising Results in Treating Pulmonary Conditions

Gossamer Bio's seralutinib has demonstrated sustained improvements in hemodynamics and functional gains over 72 weeks in treating pulmonary conditions, according to recent literature reviews. The drug's durability and disease-modifying effect are reinforced by these findings. Upcoming catalysts, including the Phase 3 PROSERA trial results expected in February 2026, are anticipated to further validate seralutinib's efficacy and safety. Analysts from H.C. Wainwright and Leerink Partners have reiterated their Buy ratings on Gossamer Bio, with price targets of $10 and $6, respectively [1].

Reference List
[1] https://www.globenewswire.com/news-release/2025/08/14/3133740/0/en/Pulmonary-Hypertension-associated-with-Interstitial-Lung-Disease-Market-to-Witness-Upsurge-in-Growth-During-the-Forecast-Period-2025-2034-DelveInsight.html